CPHI Podcast Series: Saudi Arabia’s health sector transformation: can it advance the domestic manufacture of pharmaceuticals?
The Government of Saudi Arabia is seeking to expand the private sector’s role in providing healthcare services under its Vision 2030 and National Transformation Program. Some of these ambitious goals include plans to expand the privatization of government services, incorporate health IT and digital records, and increase the number of qualified Saudi nurses and licensed medical facilities.
In recent years, the government’s efforts to curb pharmaceuticals expenditure and promote local manufacturing have resulted in a fast-growing generics market. European, US, and Indian companies have established production facilities in the country – and in particular at the King Abdullah Economic Industrial Valley – providing a full range of products including antibiotics, diabetic treatments, cardiovascular drugs, and anticoagulants. So opportunities abound for additional manufacturers to establish a presence in the Kingdom, especially in vaccines, APIs, injectables, and biologics.
In this podcast interview, Musaed Alkholief, Associate Professor at the College of Pharmacy, King Saud University, and Consultant at King Abdullah Institute for Research and Consulting Studies discusses how biopharmaceutical companies can unlock those undoubted opportunities presented by the proposed transformation of Saudi Arabia’s health sector.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...